suramin has been researched along with Fibrosarcoma in 7 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Fibrosarcoma: A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The antitumor effectiveness of cisplatin, paclitaxel, and suramin as single agents and in combination was evaluated in vivo against four lines of human pleural malignant mesothelioma xenografts in athymic nude mice, including one epithelial type and three fibrosarcomatous." | 7.70 | Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice. ( Chahinian, AP; Gluck, H; Holland, JF; Mandeli, JP; Naim, H; Teirstein, AS, 1998) |
| "To better understand the molecular basis for the cytotoxic effects of suramin, we have developed suramin-resistant DC-3F/SU 1000 cells by continuous exposure of fibrosarcoma cells to increasing concentrations of suramin." | 7.69 | Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells. ( Benchokroun, Y; Larsen, AK; Lelièvre, S, 1995) |
| "Suramin-resistant DC-3F/SU 1,000 Chinese hamster fibrosarcoma cells were obtained by continuous exposure of parental DC-3F cells to increasing concentrations of suramin (1 mg/ml final concentration)." | 7.69 | Development and characterization of suramin-resistant Chinese hamster fibrosarcoma cells: drug-dependent formation of multicellular spheroids and a greatly enhanced metastatic potential. ( Larsen, AK; Lelièvre, S, 1994) |
| " The antitumor effectiveness of cisplatin, paclitaxel, and suramin as single agents and in combination was evaluated in vivo against four lines of human pleural malignant mesothelioma xenografts in athymic nude mice, including one epithelial type and three fibrosarcomatous." | 3.70 | Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice. ( Chahinian, AP; Gluck, H; Holland, JF; Mandeli, JP; Naim, H; Teirstein, AS, 1998) |
| "To better understand the molecular basis for the cytotoxic effects of suramin, we have developed suramin-resistant DC-3F/SU 1000 cells by continuous exposure of fibrosarcoma cells to increasing concentrations of suramin." | 3.69 | Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells. ( Benchokroun, Y; Larsen, AK; Lelièvre, S, 1995) |
| " FCE 26644 and suramin, a compound possessing the same terminal half-life (t1/2) in mice and, presumably, the same mode of action, inhibit the growth of solid murine tumors, M5076 reticulosarcoma, and MXT and S180 fibrosarcoma and are inactive against B16F10 melanoma." | 3.69 | Antitumor activity of FCE 26644 a new growth-factor complexing molecule. ( Farao, M; Grandi, M; Marsiglio, A; Mongelli, N; Pesenti, E; Sola, F, 1995) |
| "Suramin-resistant DC-3F/SU 1,000 Chinese hamster fibrosarcoma cells were obtained by continuous exposure of parental DC-3F cells to increasing concentrations of suramin (1 mg/ml final concentration)." | 3.69 | Development and characterization of suramin-resistant Chinese hamster fibrosarcoma cells: drug-dependent formation of multicellular spheroids and a greatly enhanced metastatic potential. ( Larsen, AK; Lelièvre, S, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lelièvre, S | 4 |
| Larsen, AK | 4 |
| Benchokroun, Y | 1 |
| Sola, F | 1 |
| Farao, M | 1 |
| Pesenti, E | 1 |
| Marsiglio, A | 1 |
| Mongelli, N | 1 |
| Grandi, M | 1 |
| Chahinian, AP | 1 |
| Mandeli, JP | 1 |
| Gluck, H | 1 |
| Naim, H | 1 |
| Teirstein, AS | 1 |
| Holland, JF | 1 |
| Bojanowski, K | 1 |
| Markovits, J | 1 |
| Couprie, J | 1 |
| Jacquemin-Sablon, A | 1 |
| Beauchamp, RD | 1 |
| Sheng, HM | 1 |
| Bascom, CC | 1 |
| Miller, DA | 1 |
| Lyons, RM | 1 |
| Torre-Amione, G | 1 |
| Moses, HL | 1 |
7 other studies available for suramin and Fibrosarcoma
| Article | Year |
|---|---|
[Acquisition of resistance to suramin in the cells of fibrosarcoma in Chinese hamsters accompanied by morphologic modification and increased metastatic capacity].
Topics: Animals; Cricetinae; Cricetulus; Drug Resistance; Fibrosarcoma; Neoplasm Metastasis; Neoplasms, Expe | 1994 |
Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Topics: Amsacrine; Animals; Camptothecin; Cell Nucleus; Cricetinae; Cricetulus; DNA Topoisomerases, Type I; | 1995 |
Antitumor activity of FCE 26644 a new growth-factor complexing molecule.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Distamycins; Drug Administration Schedule; Drug Re | 1995 |
Development and characterization of suramin-resistant Chinese hamster fibrosarcoma cells: drug-dependent formation of multicellular spheroids and a greatly enhanced metastatic potential.
Topics: Animals; Cell Adhesion; Cell Count; Cell Division; Cricetinae; Cricetulus; Drug Resistance; Fibrosar | 1994 |
Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fe | 1998 |
Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells.
Topics: Amsacrine; Animals; Cell Compartmentation; Cell Division; Cricetinae; Cricetulus; DNA Damage; Fibros | 1992 |
Phenotypic alterations in fibroblasts and fibrosarcoma cells that overexpress latent transforming growth factor-beta 1.
Topics: Animals; Blotting, Northern; Cell Line; Embryo, Mammalian; Fibroblasts; Fibrosarcoma; Gene Expressio | 1992 |